Author:
Ninomiya Mizuki,Itoh Shinji,Takeishi Kazuki,Toshima Takeo,Yoshiya Shohei,Morita Kazutoyo,Minagawa Ryosuke,Iguchi Tomohiro,Oki Eiji,Yoshizumi Tomoharu
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Hallet J, Sa Cunha A, Adam R, Goéré D, Bachellier P, Azoulay D, et al. Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. Br J Surg. 2016;103:1366–76.
2. Beppu T, Miyamoto Y, Sakamoto Y, Imai K, Nitta H, Hayashi H, et al. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol [Internet]. 2014;21:405–13.
3. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.
4. Sakamoto K, Beppu T, Honda G, Kotake K, Yamamoto M, Takahashi K, et al. Comprehensive data of 4502 patients newly diagnosed with colorectal liver metastasis between 2015 and 2017, and prognostic data of 2427 patients newly diagnosed with colorectal liver metastasis in 2013 and 2014: Third report of a nationwide survey in Japa. J Hepatobiliary Pancreat Sci. 2023;30:570–90.
5. Beppu T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, et al. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study). Anticancer Res. 2014;34:6655–62.